Hyperdifferentiated murine melanoma cells promote adaptive anti-tumor immunity but activate the immune checkpoint system
Accumulating evidence suggests that phenotype switching of cancer cells is essential for therapeutic resistance. However, the immunological characteristics of drug-induced phenotype-switching melanoma cells (PSMCs) are unknown. We investigated PSMC elimination by host immunity using hyperdifferentia...
Saved in:
| Main Authors: | Yukie Ando, Yutaka Horiuchi, Sara Hatazawa, Momo Mataki, Akihiro Nakamura, Takashi Murakami |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2437211 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes
by: Zexing Shan, et al.
Published: (2024-07-01) -
Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy
by: Estelle Tran Van Hoi, et al.
Published: (2024-11-01) -
LAG3 immune inhibitors: a novel strategy for melanoma treatment
by: Renzheng Wu, et al.
Published: (2024-12-01) -
Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01) -
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade
by: Loulieta Nazerai, et al.
Published: (2023-12-01)